What are the indications and clinical uses of cefuroxime?

Cefuroxim Uses

Cefuroxime is a second-generation cephalosporin antibiotic indicated for treating respiratory tract infections, urinary tract infections, skin and soft tissue infections, septicemia, meningitis, gonorrhea, bone and joint infections, and for surgical prophylaxis. 1

Primary Clinical Indications

Respiratory Tract Infections

Cefuroxime effectively treats both upper and lower respiratory tract infections caused by common pathogens including Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), and Moraxella catarrhalis 1.

• Community-acquired pneumonia: Cefuroxime axetil 500 mg twice daily for 14-21 days is recommended as a first-line oral option 2
• Acute bacterial rhinosinusitis: Cefuroxime axetil demonstrates comparable activity to cefpodoxime and cefdinir against S. pneumoniae, with good coverage of H. influenzae 3
• Influenza-related pneumonia: For non-severe cases, intravenous cefuroxime or oral cefuroxime axetil combined with appropriate coverage is recommended 4

Early Lyme Disease

Cefuroxime axetil 500 mg twice daily for 14-21 days is a first-line treatment option for early localized or disseminated Lyme disease with erythema migrans 2. It demonstrates equivalent efficacy to doxycycline and amoxicillin in prospective trials.

Urinary Tract Infections

Cefuroxime treats UTIs caused by E. coli and Klebsiella species 1. Due to high urinary excretion (approximately 89% unchanged), even lower doses achieve excellent urinary concentrations—250 mg twice daily yields urinary levels averaging 1,300 mcg/mL 1.

Skin and Soft Tissue Infections

Effective against both penicillinase-producing and non-penicillinase-producing Staphylococcus aureus, Streptococcus pyogenes, E. coli, Klebsiella, and Enterobacter species 1.

Acute Otitis Media

In children, cefuroxime axetil (30 mg/kg/day in 2 divided doses, maximum 500 mg per dose) for 14-21 days is recommended as an alternative first-line agent when amoxicillin cannot be used 5. It provides coverage against beta-lactamase-producing organisms.

Surgical Prophylaxis

Urologic Procedures

For procedures with transmural incision into the urinary tract, stone manipulation, or upper tract endoscopy, cefuroxime 500 mg orally every 12 hours is listed as an acceptable prophylactic option 6.

Orthopedic Surgery

• Joint prosthesis: Cefuroxime 1.5 g IV slow, with 0.75 g re-injection if duration exceeds 2 hours, limited to operative period (24 hours maximum) 7
• Spine surgery with implants: Same dosing as joint prosthesis 7

Ophthalmic Surgery

For cataract surgery, intracameral injection of 1 mg cefuroxime after surgery is the standard prophylaxis to prevent endophthalmitis 7. This represents a major shift in practice based on strong evidence.

Intra-abdominal Infections

For mild to moderately severe infections, a cephalosporin (including cefuroxime) combined with metronidazole is recommended 8. Cefuroxime provides adequate gram-negative coverage when combined with anaerobic coverage.

Dosing Considerations

Adults

• Standard infections: 750 mg IV/IM every 8 hours 1
• Severe infections: 1.5 g IV every 8 hours 1
• Meningitis: Up to 3 g IV every 8 hours 1
• Oral (cefuroxime axetil): 250-500 mg twice daily depending on infection severity 1

Pediatric Patients (>3 months)

• Standard: 50-100 mg/kg/day divided every 6-8 hours 1
• Severe infections: 100 mg/kg/day (not exceeding adult maximum) 1
• Meningitis: 200-240 mg/kg/day IV divided every 6-8 hours 1

Renal Impairment

Dosing must be adjusted based on creatinine clearance:

• CrCl >20 mL/min: 750 mg-1.5 g every 8 hours
• CrCl 10-20 mL/min: 750 mg every 12 hours
• CrCl <10 mL/min: 750 mg every 24 hours (additional dose after hemodialysis) 1

Important Clinical Considerations

Cefuroxime demonstrates stability against many beta-lactamases, making it particularly valuable for infections caused by beta-lactamase-producing H. influenzae and M. catarrhalis 1. However, it has no activity against MRSA, Pseudomonas aeruginosa, or enterococci 1.

The oral formulation (cefuroxime axetil) is a prodrug with approximately 68% bioavailability when taken with food 9. Peak concentrations occur 2-3 hours post-dose, with therapeutic levels maintained for 5-8 hours 1.

Sequential IV-to-oral therapy (IV cefuroxime 750 mg 2-3 times daily for 2-5 days, followed by oral cefuroxime axetil 500 mg twice daily) has proven effective for community-acquired pneumonia, allowing earlier hospital discharge 10, 11.

Common Pitfalls

• First-generation cephalosporins like cephalexin are ineffective for Lyme disease and should never be substituted 2
• Cefuroxime provides inadequate coverage for atypical pathogens (Mycoplasma, Legionella)—consider adding a macrolide for severe pneumonia 4
• Protein binding is approximately 50%, which is relevant for calculating free drug concentrations in severe infections 1